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Low rates of mutation in clinical grade human
pluripotent stem cells under different culture
conditions
Oliver Thompson1, Ferdinand von Meyenn 2,3,6, Zoe Hewitt 1, John Alexander 1,7, Andrew Wood 1,
Richard Weightman 1, Sian Gregory 1, Felix Krueger 4, Simon Andrews4, Ivana Barbaric1,
Paul J. Gokhale 1, Harry D. Moore1, Wolf Reik2,5, Marta Milo 1, Serena Nik-Zainal 5,8,9,
Kosuke Yusa 5,10✉ & Peter W. Andrews 1✉
The occurrence of repetitive genomic changes that provide a selective growth advantage in
pluripotent stem cells is of concern for their clinical application. However, the effect of
different culture conditions on the underlying mutation rate is unknown. Here we show that
the mutation rate in two human embryonic stem cell lines derived and banked for clinical
application is low and not substantially affected by culture with Rho Kinase inhibitor, com-
monly used in their routine maintenance. However, the mutation rate is reduced by >50% in
cells cultured under 5% oxygen, when we also found alterations in imprint methylation and
reversible DNA hypomethylation. Mutations are evenly distributed across the chromosomes,
except for a slight increase on the X-chromosome, and an elevation in intergenic regions
suggesting that chromatin structure may affect mutation rate. Overall the results suggest that
pluripotent stem cells are not subject to unusually high rates of genetic or epigenetic
alterations.
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he presence of mutations in human pluripotent stem cells
(PSC), whether embryonic stem (ES) cells or induced
pluripotent stem (iPS) cells, is a concern for their safe use
in therapeutic applications. Indeed, in one case, a potential trial of
retinal pigment cells from an autologous iPS cell line was aban-
doned because the cells carried a mutation of unknown sig-
nificance1. Certainly some such variants are likely to have been
present in the embryos or somatic cells from which particular
PSC were derived and can be classed as ‘variants of origin’2,3.
However, the propensity of PSC to acquire genetic variants on
prolonged passage poses additional concerns, not only because of
the difficulty for their early detection4, but also their selective
growth advantages might presage malignant potential5.
Acquired genetic variants of human ES cells were first noticed
as non-random gains of particular chromosomes or fragments of
chromosomes detected by G-banding karyotypes6,7. Over suc-
ceeding years these observations were repeated in many labora-
tories as it became clear that certain chromosomal regions of
human PSC, whether ES or iPS cells, were particularly subject to
gains, notably chromosomes 1q, 12p, 17q and 20q, and the X
chromosome, or losses, notably 10p, 18q and 22p2. At the same
time, other chromosomes, notably chromosome 4, appeared
impervious to any gains or losses. More refined analyses, for
example using SNV arrays2,8, also began to reveal small structural
variants not readily detectable by G-banding cytogenetics. For
example, a small variable length CNV was found in the proximal
region of chromosome 20q in 20 human ES cell lines that were
otherwise scored as normal, diploid cells by G-banding2,9,10.
More recently, single base-pair mutations have been reported in
the TP53 gene of several human ES cell lines11,12.
It seems likely that the repetitive, non-random nature of many,
if not all, acquired mutations observed in human PSC results
from their conferring a selective growth advantage. Certainly,
chromosomal variants when initially observed in a small pro-
portion of cells in a culture commonly come to predominate
within very few passages, while experiments in which small
numbers of variant cells have been mixed with their normal
counterparts confirm the strong selective growth advantage of the
variants13. Time lapse imaging of the growth patterns of variant
and normal cells also indicates marked effects on the ability of the
cells to form viable long-term colonies after passaging by over-
coming multiple bottlenecks that restrict the ability of normal
cells to proliferate14. Further, in the minimal amplicon of
the chromosome 20 CNV, it has been possible to identify the
likely driver gene, BCL2L1, overexpression of which inhibits
apoptosis and increases survival of the variant cells15,16. Likewise,
the mutations in TP53 are likely to provide a growth advantage by
suppressing apoptosis11,12.
There have been many estimates of mutation rate in the
germline and soma, although finding consensus in the reported
rates is confounded by the variety of experimental and analytical
methodologies used in their calculation. One recent study cites
rates of 3.3 × 10−11 and 2.66 × 10−9 mutations per base-pair, per
mitosis, in the germline and soma, respectively17. By compar-
ison, Rouhani et al 20163 estimated the mutation rate in two
human iPS cell lines and one widely used human ES cell line
(H9), as 0.18 × 10−9 mutations per base-pair, per cell division,
whereas the corresponding mutation rate in somatic cells was
ten-fold higher. In another study of one human iPS cell line18
estimated a rate of 3.5 ± 0.5 base-pair substitutions per popu-
lation doubling—equivalent to about 1 × 10−9 mutations
per base-pair, per cell division. Still, little detail is known of
the mutation rates in PSC, which might arise from erroneous
repair, or from defects in mitosis, for example, leading to
chromosome non-dysjunction. Further, the possibility that some
repetitive genomic variants reflect hotspots for chromosome
rearrangements or other mutations cannot be excluded. PSC are
one of the few ‘normal’ diploid cell types that do not undergo
senescence and can be maintained indefinitely in vitro. Other
diploid somatic cells undergo senescence, whereas other easily
accessible cells that can be grown indefinitely are likely to be
transformed cancer cells. Further, cell cycle control in PSC
differs with respect to the lack of key checkpoints, notably the
G1/S checkpoint19, or the CHK1 checkpoint in S-Phase DNA
replication resulting in apoptosis of PSC in response to DNA
replication stress, in contrast to somatic cells20. This might
reflect the relation of PSC to the rapidly dividing pluripotent
cells of the early embryo for which there may be a survival
advantage if cells suffering DNA damage undergo apoptosis
rather than repair the damage.
Most studies in human PSC to date have been concerned with
mutations providing a selective advantage, as these are the most
frequently and easily detected when screening cell lines. However,
estimating the underlying mutation rate is more difficult and can
be confounded by the emergence of an advantageous or cell-lethal
mutation, both of which could bias the mutational load of the
population. To de-couple mutation from selection it is necessary
to distinguish acquired de novo mutations, occurring during
prolonged cell culture, from variants-of-origin mutations (i.e.
those already present in the parental cells) and to estimate the
frequency of their appearance before the selective overgrowth of
any advantageous mutations.
In this study, to determine the rate and types of mutation that
occur during culture of human PSC, we have used a cloning
strategy coupled with whole-genome-, whole-genome bisulfite-
and RNA-sequencing to compare two well characterised, clinical
grade human ES cell lines, as well as the effects of culture in the
presence of a Rho-kinase inhibitor, now commonly used in
routine culture of human PSC, and of culture under low oxygen
(5% O2) conditions. We have tested whether the mutations are
randomly distributed throughout the genome or clustered in
regions related to chromatin structure and gene expression. Our
results indicate that the mutation rate is low compared to esti-
mates in somatic or cancer cells and can be further reduced by
culture under low oxygen conditions. Furthermore, the muta-
tional signature of human PSC is similar to that of other cultured
human cells, but low oxygen culture does alter the frequency of
some types of base-pair change associated with oxidative damage.
Results
Experimental design. For these experiments, we chose two male
human ES cell lines, MShef4 and MShef11 that we had derived
under GMP-like conditions suitable for their potential clinical use
in regenerative medicine. During their initial derivation, banking
and characterisation, no karyotypic variants of MShef4 had been
observed, and it was designated, a priori, as a genetically more
stable line. By contrast, several cultures of MShef11, though not
those used to produce master and working banks, were found to
contain chromosomal aberrations (unpublished observations)
and so this line was designated, a priori, as genetically less stable.
To assess the mutation rates in these cells, the strategy we
adopted was to produce a clonal subline that was karyotypically
diploid, grow that clone for a defined period, and then produce a
series of subclones that were subjected to whole-genome
sequencing, as well as whole-genome bisulfite sequencing and
RNA sequencing (Fig. 1).
Mutation rate between cell lines and growth-conditions.
Whole-genome sequence (WGS) data were analysed using the
CaVEMan variant detection algorithm (Cancer Genome Project,
https://github.com/cancerit/CaVEMan). Following quality control
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12,555 SNVs were identified for subsequent analysis (see Methods
of details).
The rate of somatic substitution mutation in each cohort of
MShef4 and MShef11 subclones was assessed by calculating the
number of de novo SNVs acquired per day of culture, per base-
pair of sequenced haploid genome21 (Supplementary Data 1). The
mutations rates for MShef4 and MShef11 grown in standard
conditions were both low (0.37 × 10−9 and 0.28 × 10−9 SNVs
per day, respectively) and not significantly different (P= 0.084)
(Fig. 2a). The mutation rate for MShef11 in the presence of
Y27632 was not significantly different, at 0.3 × 10−9 SNVs
per day, per base-pair (P= 0.6). However, MShef11 grown under
low oxygen did have a significantly lower mutation rate compared
to standard conditions (P= 0.000034) with a median of 0.13 ×
10−9 SNVs per day per base-pair, a reduction of 54%.
Distribution of base-pair mutations across the genome. To
determine whether mutations occurred randomly and were dis-
tributed uniformly across the genome, or if there was an
enrichment of mutations on particular chromosomes, we quan-
tified the haploid mutation rate per chromosome, per day,
per sequenced base-pair21 and compared each to the genome-
wide mutation rate. Due to a high level of noise generated from
aligning and mapping mutations to the Y chromosome, we
excluded this from this analysis. When we applied paired Mann-
Whitney testing with Bonferroni correction to compare the
median mutation rates of each chromosome to the respective
genome-wide rate under each growth condition, none of
the autosomes showed significant deviation from the genome-
wide rate. However, the X chromosome showed an elevated
mutation rate in all growth conditions (Fig. 2b), although this was
significant only in the MShef4 standard and MShef11 low oxygen
conditions (P= 0.007; P= 0.034). Nevertheless, when data from
all growth conditions were combined into a single dataset, the
mutation rate of genes on the X chromosome, but on none of the
autosomes, continued to show a small but significantly (p < 0.05)
elevated mutation rate.
We next measured the haploid mutation rates of intergenic,
intronic and exonic regions, as annotated in the GRCh37 genome
assembly, and normalised to the base-pair content of each class of
feature (Fig. 2c). For these three features there was no difference
in mutation rate between MShef11 grown in standard conditions
or with Y27632, but the mutation rates of all features were
reduced in MShef11 grown under low oxygen (intergenic P= <
0.000049; intronic P= 0.00006; exonic P= 0.043). There was a
significant difference between the intronic mutation rate of
MShef4 and MShef11 grown in standard conditions, with MShef4
having the higher mutation rate (P= 0.04). Within each growth-
condition group, the median mutation rates of introns and exons
were similar, but intergenic DNA had approximately double the
mutation rate of exons or introns. This may be a result of
preferential DNA repair in genic regions, as has been reported by
others22,23. We asked if the elevated mutation rates seen on the X
chromosome was due to a high proportion of intergenic DNA,
but it does not show an unusually high intergenic DNA content
(Supplementary Fig. 5a, upper panel) suggesting that the elevated
mutation rate of this chromosome is not linked to its intergenic
content alone. We also considered the GC nucleotide content of
each chromosome, given the higher mutability of GC compared
to AT nucleotides. Again, the X chromosome does not possess an
unusually high GC content (Supplementary Fig. 5a, lower panel).
We also measured the mutation rates within a variety of other
genomic features (Supplementary Fig. 5b). In most cases, we
found a similar pattern of difference between groups, with
subclones derived from low oxygen parental clones displaying a
significantly lower mutation rate than other groups. Two
exceptions that showed slightly elevated mutation rates across
all groups were CpG islands and transcription factor-binding
sites (TFBS). Both showed a slightly higher mutation rate
than other features (with the exception of intergenic regions),
with no significant differences in mutation rates between groups,
suggesting that such genomic regions are particularly susceptible
to mutation. However, given the small number of subclones that
acquired mutations in these regions we could not draw further
conclusions on the significance of this finding. The mutation rates
MShef4
Starting culture
Parental
clones
Clone
Reclone
Clone
Reclone
Standard
109 days
Standard Y27632 at passage 5% O2
111 days 115 days
+28 days
normoxia
111 days
E4 E7 F1 F4 G2 G8B8
J O P K L Q N
Expand under
different conditions
Subclone
cohorts
MShef11
Fig. 1 Schematic representation of the experimental design. Schematic representation of the experimental regime, in which MShef4 and MShef11 human
ES cell lines were cultured for an extended period under different growth-conditions. Stock cultures of MShef4 and MShef11 were cloned by single-cell
deposition to ensure a homogeneous starting point. A clone of each was then recloned to generate Parent Clones that were then cultured under the
different growth-conditions for a period exceeding three months—MShef4 clone B8, standard conditions, 109 days (19 passages); MShef11 clones E4 & E7,
standard conditions, 111 days (25 passages); MShef11 clones F1 & F4, standard conditions + Y27632, 115 days, (25 passages); MShef11 clone G8 low
oxygen, 111 days (25 passages) to give subclone cohort N, and 111 days + 28 days in standard oxygen (25+ 6 passages) to give subclone cohort Q. At the
end of the expansion period cultures were recloned again into standard conditions to obtain subclone cohorts (J, O, P, K, L, N and Q, respectively, as
shown), from which genetic material was extracted as early as possible (5 passages) for sequencing analysis.
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over a variety of histone marks were also calculated (Supple-
mentary Fig. 5b). In the case of three types of histone mark
(H3K4me1, H3K4me3, and H3K36me3), MShef4 had slightly
higher though significant mutation rate than MShef11 grown
under standard conditions (P= 0.029; P= 0.008; P= 0.023). In
two cases (H3K9me3 and H3K27me3) MShef11 grown in low
oxygen had a significantly lower mutation rate than MShef11
grown in standard conditions (P= 0.0008; P= 0.013).
Pattern of mutational pressure and mutation signatures. It is
possible to extract unique mutational signatures from WGS data
by examining the frequencies of different types of base substitu-
tion and the up- and downstream context surrounding the
SNV24,25 (Supplementary Data 2). These signatures can provide
information about the type of mutational stress experienced
by cells.
Low-resolution mutation spectra showed that MShef4 and
MShef11 grown in standard conditions or with Y27632 had a very
similar pattern of base substitution. However, subclones derived
from low oxygen culture had a slightly different pattern of
substitution mutations compared to the other conditions (Fig. 3a)
with significantly fewer C > A transversions (P= 0.047) and
significantly more T > C transitions (P= 0.045) compared to
standard conditions
High-resolution spectra (considering base-pairs flanking each
mutation) produced a mutation profile that was similar between
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Fig. 2 Mutation rate and genomic distribution of single-nucleotide variant mutations in different growth-conditions. Box and whisker plots showing
haploid mutation rates and genomic distribution of single-nucleotide variant mutations in subclones of MShef4 (N= 20) and MShef11 (N= 19) grown
under standard conditions, and subclones of MShef11 cultured with the rho-kinase inhibitor Y27632 at passage (N= 20) or cultured in low oxygen (N=
21). Boxes represent 25th–75th percentiles; whiskers show the min and max ranges; horizontal lines indicate the median values. a The median mutation
rates (shown below each plot) for MShef4 and MShef11, cultured in standard conditions, and MShef11 cultured with the rho-kinase inhibitor Y27632 were
not significantly different. However, MShef11 cultured in low oxygen exhibited a ~54% lower mutation rate (unpaired two-tailed t-tests with Welch’s
correction; P= < 0.0001). ns: P > 0.05; *P≤ 0.05; **P≤ 0.01, ***P≤ 0.001; ****P≤ 0.0001. b Across all chromosomes only the X-chromosome mutation
rate deviated from the genome-wide rates, being elevated in all growth conditions, although only significant in MShef4 and MShef11 under low oxygen,
assessed by independent pairwise two-tailed Mann-Whitney tests comparing the median genome-wide rate in each condition with that of each
chromosome (Bonferroni-adjusted P= < 0.007; P= < 0.034). When data from all growth conditions were combined, the elevated X-chromosome
mutation rate remained significant (P= < 0.05). ns: P > 0.05; *P≤ 0.05; **P≤ 0.01, ***P≤ 0.001; ****P≤ 0.0001. c Across coding and non-coding regions,
normalised to the genomic DNA content of each class of region, under each growth-condition intergenic DNA showed higher mutation rates than exons
and introns. For intergenic DNA: MShef11 standard vs MShef11 low oxygen P < 0.001; For intronic DNA: MShef4 standard vs. MShef11 standard P= 0.004,
MShef11 standard vs MShef11 low oxygen P= 0.017; For exonic DNA: MShef11 standard vs MShef11 low oxygen P < 0.0001. Asterisks indicate level of
significance between groups assessed by independent pairwise two-tailed Mann-Whitney testing. ns: P > 0.05; *P≤ 0.05; **P≤ 0.01, ***P≤ 0.001; ****P≤
0.0001. Source data are provided in Supplementary Data 1.
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Fig. 3 Pattern of base substitutions and mutation signatures. a Bar and dot chart showing low-resolution mutational spectra and proportions of each of
seven point mutation classes detected in MShef4 standard (N= 20), MShef11 standard (N= 19), MShef11+ Y27632 (N= 20), and MShef11 low oxygen
(N= 21) subclones. Bars indicate the mean proportion of each class of mutation for each cell line/growth-condition group; dots indicate individual
subclones in each group. C > A transversions and C > T transitions are most prevalent in the data. A two-tailed t-test showed MShef11 cultured in low
oxygen to have a significant reduction in C > A transversions compared to standard conditions (P= 0.037) whilst Wilcoxon testing also showed a small
increase in T > C transitions (P= 0.045). b High-resolution mutational spectra derived from the combined mutation data all subclones grown in each
growth-condition. Each of the six possible point mutations is subdivided into 16 classes on the basis of the 5’ and 3’ nucleotides flanking the mutation,
resulting in 96 possible substitution classes. C:G > A:T and C:G > T:A mutations are most prevalent in the data. These spectra can be correlated with
30 mutation signatures annotated in the Catalogue of Somatic Substitutions in Cancer (COSMIC) database53 to explore the aetiology of mutation.
c Dendrogram showing the similarity of all growth-condition groups based on their mutational profiles. MShef4 and MShef11 cultured in standard
conditions exhibited the most similar mutational profiles, whereas the low oxygen condition is the most dissimilar in mutation profile compared to all other
groups. Source data are provided in Supplementary Data 2.
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cell lines and growth conditions, with a predominance of C > A
transversions (particularly in the GCA and TCT context) and C >
T transitions (Fig. 3b). When we compared the mutational profile
of each condition with 30 annotated in the Catalogue of Somatic
Mutations in Cancer (COSMIC) database, our data correlated
most closely with COSMIC signature 18 (cosine correlation=
0.873), which is associated with oxidative stress and is a hallmark
of in vitro cell culture25,26. The reduced C > A component
observed in MShef11 under low oxygen fits with a model of
reduced oxidative stress, as oxidative species predominantly affect
guanine (which is captured in the C > A class). Similarity-
clustering showed that MShef4 and MShef11 grown in standard
conditions acquired the most similar mutation profiles, followed
by MShef11 cultured with Y27632, and the low oxygen condition
as an outgroup (Fig. 3c) indicating that low oxygen culture
induced the largest difference in mutational profile of all
conditions tested.
INDELs and structural variants. To detect INDELs we used the
PINDEL INDEL-calling algorithm (github.com/genome/pindel).
Following quality control and excluding calls with length greater
than 100 bp, as well as 291 calls that were recurrent in subclones
of the same cohort, a total of 1171 de novo INDELs remained for
analysis including single-base INDELs [572 insertions; 573 dele-
tions; 26 complex] (Supplementary Figures 1–4; Supplementary
Data 3). Out of 1171 INDELs, 578 are single-base INDELs of
which 350 are insertions and 228 are deletions. Taken together,
the median INDEL mutation rate was ~10-fold lower than that of
base-pair substitutions (Fig. 4a). As with SNVs, we observed a
lower mutation rate in MShef11 grown in low oxygen compared
to MShef11 grown under standard conditions (0.15 × 10−10 vs
0.26 × 10−10 INDELs per day, per base-pair; P= 0.02) and we
observed a significant difference in median deletion mutation
rates between MShef11 grown under low oxygen vs. MShef11
grown in standard conditions (0.05 × 10−10 vs 0.16 × 10−10
deletions per day, per base-pair; P= 0.0008) (Fig. 4a, b). We
detected no systematic deviation in INDEL mutation rates per
chromosome (Supplementary Fig. 6a), and we did not find any
enrichment of INDELs at regions associated with common
recurrent change in human PSC (for example chromosomes 1q,
12p, 17q, 20q). Due to the overall low number of INDEL muta-
tions, it was not possible to make further meaningful analysis of
rates within different regions of the genome.
All growth-condition groups showed some evidence of
larger structural rearrangements. Using the BRASS structural
rearrangement-calling algorithm (www.github.com/cancerit/
BRASS), we detected, in different subclones, three deletions, del
(2)(p16.1p16.1), del(10)(q26.13q26.13) and del(12)(q22q22), two
tandem duplications, dup(4)(q22.2q22.2), dup(12)(q14.3q14.3)
and one translocation,?der(20)t(11;20)(q21;p11.23). In addition,
we found one translocation,?der(12)t(8;12)(q21.11;p11.22), in two
subclones of one cohort of MShef11 under normal culture
conditions, most likely reflecting a mutation early in the culture
of the parent clone (Supplementary Table 1). Of these variants,
one translocation involved chromosome 12, and another involved
chromosome 20, a deletion involved chromosome 10 and a
tandem duplication and a deletion involved chromosome 12.
These chromosomes are all well known to be associated with
common karyotypic changes in human PSC but, with the
exception of a breakpoint in a region of chromosome 10p
associated with repeated deletions2, none of the break points
involved in the variants observed here were in regions associated
with the common karyotypic changes of these chromosomes.
However, there were too few such rearrangements to permit a
meaningful analysis.
De novo mutations in genes. Across all subclones, we detected
5695 de novo SNVs in 4095 genes in the GRCh37 genome
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Fig. 4 Mutation rate and genomic distribution of insertion and deletion mutations in different growth-conditions. a Box and whisker plots showing
haploid mutation rates all INDELs in subclones derived from clones grown in different conditions. MShef11 subclones derived from low oxygen (N= 21)
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assembly (including those unannotated) (Supplementary Data 1)
4694 mutations mapped to introns and 225 SNVs occuured in
exons resulting in 90 missense, 7 nonsense and 27 synonymous
ammino accid substitutions. A further 985 SNVs mapped to
regions within 1 kb up- or downstream of genes, 114 to 5’ and 3’
untranslated regions (UTRs), 27 to genes encoding non-coding
RNAs, and 15 to splice regions or essential splice sites (Supple-
mentary Fig. 6b). We further analysed whether nonsense muta-
tions or mutations in splice sites had any effects on transcript
levels (Supplementary Table 2). In only two of these mutations
did we find evidence of reduced mRNA levels. MShef11+
Y27632 subclone K2 harbored a nonsense mutation in the gene
DNAJC6, which exhibited a 43% decrease in expression compared
to the mean of other subclones in this cohort (2.7 vs. 4.7) while
MShef4 subclone J13 harbored a splice region mutation in the
gene C11orf73, which exhibited a 32% decrease in expression
compared to the mean of its cohort (8.4 vs. 12.34). Eight genes
acquired INDELs that produced frame-shift mutations, each
occurring in a unique subclone (Supplementary Data 3).
Although some of the affected genes are expressed in the undif-
ferentiated cells (Supplementary Data 4), we did not note any that
have any obvious special significance for human PSC biology.
We did not find any de novo mutations in genes known to be
important in maintaining stem cell pluripotency and homeostasis,
nor any mutations in BCL2L1, which is frequently amplified in
human PSC cultures, or the common 20q11.21 copy-number
variation that results in its duplication. A recent study identified a
subset of human PSC lines harbouring multiple mutations in the
TP53 gene, which are frequently seen in cancers and which may
drive selective advantage in vitro12. However, we did not detect
any TP53 point mutations nor INDELs in any of our 80
independent subclones.
We also compared our data to the NCBI public archive of
clinically relevant variants (ClinVar) and found a single de novo
SNP in one MShef4 subclone, a C > T transition in the penultimate
3’ exon of SNCAIP—an α-synuclein-interacting protein on
chromosome 5q, associated with Parkinson’s disease. This
substitution has an allelic frequency of 0.00001647, based on
60,706 individuals of diverse genetic backgrounds in the Broad
Institute Exome Aggregation consortium. It results in a missense-
coding mutation R806C but is not classed as clinically pathogenic.
It lies immediately 5’ to a second, clinically recognised germline
missense-coding SNP also considered to be clinically benign.
Overall, the absence of clinically recognised mutations in our
data is reassuring, as it suggests that even following prolonged
culture the acquisition of known, pathological mutations is
extremely low.
Properties of mutated genes. We searched for characteristics of
genes that had acquired de novo SNVs, in order to understand
what might render them more, or less susceptible to mutation
(Supplementary Data 4). For this analysis, we defined a gene as
the entire annotated region from the GRCh37 genome assembly,
comprising introns, exons and UTRs. To measure the relation-
ship between gene size and mutation, we binned genes into 20 kb
size bins, and calculated the mean mutational load (SNVs per
base-pair of gene) per bin. In a model of stochastic mutation, we
would predict an equal mutational load across all genes. How-
ever, we observed mutational load decreasing with increasing
size, in genes up to 20 kb (Fig. 5a) indicating that the smallest
genes were disproportionately mutated. Further, the size dis-
tribution of the top 10% most-highly mutated genes was sig-
nificantly smaller than that of the bottom 10% of their least-
mutated counterparts (Fig. 5b). GO analysis using the PAN-
THER (Protein ANalysis THrough Evolutionary Relationships;
(http://www.pantherdb.org/). Classification System highlighted
some association of these genes with various signalling pathways,
but as the mutations occurred across independent subclones and
growth conditions, we cannot ascribe any particular significance
to these enrichments (Supplementary Table 3) (Supplementary
Data 5). From these data we conclude that mutation does not
occur stochastically over genes, and that other mechanisms must
contribute to their mutability.
Active transcription has been identified as a bottleneck for
genomic stability, as DNA replication, repair, and transcriptional
machinery can physically interfere with one another (reviewed in
ref. 27). Further, local differences in chromatin structure may
render those regions of a gene more or less susceptible to
mutation. To test the relationship between transcription, gene
expression, and mutation in our data we measured the proportion
of genes harbouring mutation at varying distance from their
transcription start sites (TSS). We found the prevalence of
mutation increased with increasing distance from TSS (Fig. 5c), as
has been observed previously24.
To analyse the relationship between gene expression and
mutation we used the gene expression estimates from RNA-seq
data for MShef4 and MShef11 subclones derived from each
growth-condition (Supplementary Data 4). We calculated FPKM
expression values of mutated genes in each cell line and growth
condition independently, and excluded those genes with log
(FPKM) values below 1, considering them to be unexpressed. We
then correlated the expression levels of mutated genes with their
corresponding mutational load (mutations per bp) and found a
trend of positive correlation between gene expression and
mutational load (Fig. 5d). To further quantify this effect, we
used a Linear Mixed Effect model (LMER) using the formula:
Mutation_Load ~ Gene_Expression+Mutation_Effect+ (1 |Gen-
e_Length). This accommodates the non-random effect of the gene
length as described above and the impact of that mutation type
can have on gene expression. The LMER reached convergence
and confirmed the positive trend as pictured in the scatter plots;
we also found that the LMER applied to mutated genes that were
not expressed or with very low expression, described an opposite
correlation trend (Supplementary Figure 7).
Epigenetic changes across the genome. Epigenetic changes have
been detected in human PSC, although evidence that they may
provide growth advantages is less clear. Loss of X-inactivation,
termed erosion, has been reported a number of times in female
human PSC28,29 and may correlate with the observation that
gain of X chromosomes may provide a growth advantage to
human PSC as it is one of the non-random genetic changes
commonly seen2,4. To look for epigenetic changes, we used
whole-genome bisulphite sequencing (WGBS) data obtained
from the original starting cultures of MShef4 and MShef11
grown in standard conditions, the parental clones derived from
those cultures and expanded in different conditions, and the
subclones derived from those parental clones (Fig. 1). We
measured DNA methylation levels over a range of genomic
features annotated in the GRCh38 genome assembly: tiled
regions containing 100 CpGs across the entire genome, CpG
islands, promoters, and annotated genic regions (Supplementary
Data 6–9). We then compared cell lines and growth-conditions
at different stages of the experiment.
The original starting populations of MShef4 and MShef11
grown in standard conditions (Fig. 1) had comparable methyla-
tion levels to one another across all genomic features (Supple-
mentary Fig. 8). In most cases, the parental clones derived from
those starting cultures also had similar methylation patterns to
one another. However, Wilcoxon rank-sum testing showed that
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both parental clones grown in low oxygen (G8 and G2) had a
significant decrease in methylation compared to those grown in
standard conditions (both P= < 0.001), with a particularly large
decrease in G8 and a mean reduction of 3.6% (Fig. 6a). The
reduction in methylation seen under low oxygen appeared
reversible, as the subclones derived from G2 and G8 in low
oxygen but expanded under standard conditions prior to WGBS
showed reversion back to 91% methylation, equivalent to their
counterparts from standard conditions. (Fig. 6a). Overall we
found a weak relationship between promoter methylation and
gene expression.
MShef4 subclones (J1-20) as a group showed striking hyper-
methylation of CpG island-containing (CGI) promoters com-
pared to MShef11 subclones (Supplementary Fig. 8). To test if this
effect was due to a single aberrant subclone skewing the grouped
data, or if the hypermethylation had occurred in many
independent subclones, we used higher-depth WGBS data from
a subset of seven independent MShef4 subclones (Supplementary
Data 10, 11) and compared the methylation levels of each to their
parental clone, B8. Each subclone showed substantial hyper-
methylation of a subset of CpG island-containing promoters
(Fig. 6b, top panels; Supplementary Fig. 9, left panels). This
showed that the effect was not restricted to a single aberrant
subclone and had likely occurred in all subclones in the cohort
following single-cell deposition and expansion. Of the 11,677 CGI
promoters measured, 1905 were hypermethylated by at least 20%
across all seven subclones (Supplementary Data 12) although the
levels were highly variable. However, only two CGI-containing
promoters were hypermethylated by an equivalent level (±5%)
across all subclones (these were directly upstream of the long
non-coding RNA FP236383.12 and the ribosomal gene RNA5-
8S5, located on chromosomes 21 and 22, respectively) indicating
no consistency in the patterns of hypermethylation and no
common predecessor with the epigenetic alterations. In contrast,
methylation of non-CGI promoters was similar between each
subclone and its parental clone, B8 (Fig. 6b, bottom panels;
Supplementary Fig. 9, right panels). We measured the expression
of de novo methyltransferase genes (DNMTs) in MShef4
subclones (Supplementary Data 13) and found significantly
elevated expression of DNMT3B and DNMT3L (P= 7.2−8; P=
2−8) compared to MShef11 subclones (Fig. 6c). Both genes are
involved in de novo methylation, and their relative overexpres-
sion in MShef4 subclones may account for the observed
hypermethylation of CpG island-containing promoters.
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Fig. 6 Epigenetic changes. a Beanplots showing global DNA methylation levels of MShef11 starting cultures, parental clones grown in standard or low
oxygen conditions, and the subclones derived from those conditions. Methylation was assessed over tiled probes across the genome, each containing
100 CpGs. Both parental clones grown in low oxygen show a small decrease in methylation, particularly clone G8. This decrease in methylation was
reversible, as subclones derived from low oxygen revert to normal methylation levels following expansion in standard conditions. Source data are provided
in Supplementary Data 6. b DNA methylation of promoters in MShef4 subclones (N= 20). Promoter regions were defined as regions surrounding
transcription start sites, with 1500 kb upstream and 500 kb downstream context. Beanplots (left panels) show DNA methylation levels of promoters with
and without CpG islands, in a randomly selected subset of MShef4 J subclones. For both classes of promoter, the starting culture and the parental clone,
B8, derived from that starting culture had comparable methylation levels, whereas each J subclone showed hypermethylation of a subset of CpG island-
containing promoters compared to its parental clone, B8. Density scatter plots (right panels) show the distribution of promoter methylation levels between
the MShef4 starting culture and its derived parental clone, B8, and between the parental clone B8 and an example subclone, J1. The density scatter plots
show comparable levels of non-CpG island-promoter methylation between starting culture material and parental clone B8, but hypermethylation of CpG
island-containing promoters in subclone J1 compared to parental clone B8. Source data are provided in Supplementary Data 9–12. c Top panel; heatmap
showing the relative expression of de novo methyltransferase (DNMT) genes in MShef4 (N= 20) and MShef11 (N= 19) subclones from standard conditions.
Lower panel; box and whisker plots showing the normalised expression counts (fragments per million reads) for DNMT genes in MShef4 and
MShef11 standard subclones. Both DNMT3B and DNMT3L are more highly expressed in MShef4 subclones (P= 7.2−8 and P= 2−8). Boxes represent the
25th–75th percentiles of the data; whiskers show the min and max range of the data; horizontal lines indicate the median value. ns: P > 0.05; *P≤ 0.05;
**P≤ 0.01, ***P≤ 0.001; ****P≤ 0.0001. Source data are provided in Supplementary Data 13.
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Differences in imprint methylation and expression. Given the
epigenetic differences observed in our data, we examined
imprinting in the subclones, which is regulated by the epigenetic
status of imprint control regions (ICRs). Although imprinting in
human PSC seems to be relatively stable, loss of imprints are
sometimes seen, though with unknown significance30. In con-
trast, naive human PSC31,32 have less stable imprinting. For this
analysis, we integrated WGBS and RNA-seq data to look for
differences in ICR methylation and related imprinted gene
expression (Supplementary Data 14). Comparing the methylation
status of 26 known ICRs in the starting cultures, in the parental
clones grown in different growth-conditions, and in their
respective subclones, the mean ICR methylation was 64% across
all groups, and close to the expected 50% CpG methylation
resulting from one fully methylated and one unmethylated par-
ental allele. Individual ICRs ranged between 7.6–96.9%, and
methylation of some ICRs fluctuated between groups (Fig. 7a).
Closer examination showed differences in the overall methylation
of ICRs, between starting cultures, the parental clones and the
subclones. The MShef4 starting culture had higher average ICR
methylation than its MShef11 counterpart; MShef11 clones
grown in low oxygen had elevated ICR methylation compared to
their parental culture, and all subclone groups acquired higher
ICR methylation compared to their clones-of-origin (Supple-
mentary Fig. 10).
To examine the effects of differences in ICR methylation, we
measured the expression of 75 imprinted genes in our
subclones and compared cell lines and growth-condition
groups (Supplementary Data 14). All MShef4 subclones
showed differential expression of several clusters of imprints,
relative to MShef11 (Supplementary Fig. 11) with one cluster
having comparatively increased expression, and at least two
clusters showing reduced expression. In particular, expression
of H19, IGF2, and NLRP2 was systematically different between
MShef4 and MShef11 subclones. Furthermore, imprint expres-
sion between MShef4 subclones was more homogenous than
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Fig. 7 Imprint methylation and expression. a Heatmap showing the methylation levels of 26 imprint control regions (ICRs) in starting cultures, parental
clones, and subclones, grouped by cell line and growth-condition. Individual ICRs show a wide range of methylation levels with some notable inter- and
intra-group variation. Source data are provided in Supplementary Data 14. b Top panel; heatmap showing the relative expression of four selected imprinted
genes: FAM50B, H19, ZIM2, and MIMT1 in MShef4 and MShef11 subclones. Both FAM50B and H19 are more highly expressed in MShef4 subclones; ZIM2
and MIMT1 are more variable in their expression. Lower panel; dot plots showing the correlation between ICR methylation and the expression of four
imprinted genes, in a subset of MShef4 and MShef11 subclones with WGBS data of sufficient depth to permit such analysis (selected subclones indicated
by asterisks in top panel). In all cases differences in gene expression correlate with a change in ICR methylation. Source data are provided in Supplementary
Data 15.
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between MShef11 subclones, which showed greater variation
within, and between growth-condition groups (Supplementary
Fig. 12). In a set of subclones that showed significant variation in
imprint expression, and for which sufficient WGBS depth was
available, four imprinted genes, MIMT1, ZIM2, FAM50B and
H19, all showed an inverse correlation between ICR methylation
and gene expression as anticipated (Fig. 7b). Overall, the
methylation patterns were subject to environmental growth
conditions, in a way that was cell-line dependent.
Discussion
Understanding genetic and epigenetic change in human PSC
during in vitro culture is important in the context of regenerative
medicine, as these cells represent a starting point for stem cell-
based therapeutics. Thus, developing culture conditions that
minimise change is important for improving safety in clinical
applications of human PSC-derived therapeutics. It is encoura-
ging that following culture over an extended period of time and
multiple passages, both the human PSC in this study acquired a
relatively low burden of single-nucleotide base substitutions, and
none of the common genetic variation seen in human PSC. This
is consistent with the view that the common non-random genetic
changes observed in human PSC are driven by the selective
growth advantage of rare but random mutations. However, esti-
mating the underlying rate of mutation in PSC is difficult because
by the time mutants become detectable their frequency may be
grossly distorted by the effects of selection of those that offer a
growth advantage. The clongenic strategy that we adopted to
obviate this difficulty is, however, complex and expensive, so that
it was only feasible to analyse two human ES cell lines, and the
necessary production and selection of clones with which to carry
out the analysis might itself have introduced distortions. Never-
theless, the rates we observed under normal growth conditions
(0.37 × 10−9 and 0.28 × 10−9 SNV per day, for genetically inde-
pendent human ES cell lines (MShef4 and MShef11, respectively)
are not significantly different and are comparable with two other
recent studies of human PSC (0.18 × 10−9 and 1 × 10−9 SNV per
base-pair, per cell division, respectively)3,18. They are sub-
stantially lower than the mutation rates estimated in somatic cells.
The two ES cell lines used in our present study are mostly likely
genetically unrelated, and one was derived from a frozen embryo
and one from a fresh embryo. By contrast the lines studied by
Rouhani were iPS cell lines, derived by reprogramming. That the
mutation rate in all of these lines was comparably low, suggests
that this may be a feature of PSC in general, irrespective of their
means of derivation. It is also notable that in a study of a single
locus, Aprt, in mouse ES cells,33 concluded that the mutation rate
in mouse ES cells is substantially lower than in corresponding
somatic cells.
An increasing number of reports link culture conditions and
reagents to the occurrence of genetic variants7,34–36. Clearly,
existing in vitro culture conditions are sub-optimal for the
maintenance of genetically normal stem cells and, while the
mechanisms that underlie genetic variation are unclear, it is
possible that exposure to factors such as mutagenic chemical
components in growth media, and the accumulation of reactive
oxygen species could drive mutation. Importantly, though, the
Rho-Kinase inhibitor, Y27632, which is now widely used in PSC
culture did not affect the mutation rate despite concerns that its
anti-apoptotic effects might enhance the appearance of muta-
tions. However, our data did show about a 50% reduction in
mutation rate in cells cultured under low (5%) oxygen compared
to standard conditions, which may be a consequence of reduced
levels of reactive oxygen species generated through oxidative
stress. This oxygen level, which has also been reported to affect
the behaviour and differentiation capacity of PSC (e.g.37,38), more
closely mimics the oxygen tension experienced in the early
embryo39. Our results do suggest a benefit for maintaining
human PSC cultures in a low oxygen environment, though to
avoid exposure to fluctuating oxygen levels, for example to
atmospheric oxygen during passaging and other manipulations,
this requires the use of a dedicated low oxygen workstation, as we
have done in this study.
The mechanisms underlying mutation have been investigated
most thoroughly in the context of cancer, where the patterns of
base substitution observed in specific cancer types has been
deconvoluted and linked to their causative environmental agents
or to aberrant biological mechanisms24,25. In this study, cultures
from all growth-conditions showed a strong correlation with a
mutation signature frequently detected in cultured cells and
linked to oxidative stress (COSMIC signature 18). Similar
observations were also made in other studies of the mutational
burden in human iPS cells40–42. Consistent with this, low oxygen
culture induced a change in mutational signature, resulting in a
reduced C > A component in signature 18.
A stochastic model of mutation would predict a roughly equal
rate of change across all regions of the genome. Indeed, we found
that mutation was evenly distributed across the chromosomes,
with the exception of the X chromosome, which exhibited a
slightly elevated mutation rate compared to the genome-wide
average. Because MShef4 and MShef11 are both male cell lines it
is possible that this is a male specific phenomenon. For example,
the absence of a second copy of the X chromosome for repair by
homologous recombination, or increased transcription rates from
X chromosomes in male PSC to compensate for the presence of
two active X chromosomes in female PSC, may partly account for
the elevated mutation rate. Nevertheless, we did find differences
between genomic regions, with an elevated mutation rate in
intergenic DNA compared to coding-region DNA, though in the
genic regions we found no difference in mutation rate between
exons and introns. This suggest that differences in chromatin
structure or functional activity render those regions more or less
mutagenic and that an antagonistic relationship between tran-
scription and DNA repair27 may be compensated by preferential
DNA repair in genic regions, as has been reported by others22,23.
On the other hand, high transcriptional activity may hinder DNA
repair processes as we did find a weak correlation between
mutational load and gene activity, a relationship that has pre-
viously been observed in yeast43, though in contrast to observa-
tions in tumor cells24. That discrepancy might reflect differences
in cell cycle control and response to DNA damage in embryonic
cells compared to somatic cells20.
Further to the rates of change caused by mutation, we also
observed significant differences in the epigenetic status of the two
human ES cell lines we studied. Previous studies of PSC have
detected cell-line-specific and culture-induced epigenetic changes
in general DNA methylation34,44 and at specific loci such as
imprint control regions2,30,45. We detected a small reduction in
global DNA methylation levels in MShef11 clones cultured in low
oxygen, which was reversible following subcloning and expansion
in standard oxygen conditions. In mouse ES cells, resetting to a
naive state is accompanied by hypomethylation of the genome to
a level comparable with the inner cell mass (ICM) 31,46,47. Thus, if
low oxygen culture mimics conditions in the early embryo, we
might expect to see some level of hypomethylation. However, the
small decrease in methylation detected in this study (mean
reduction of 3.6% in CpG methylation in low oxygen cultures) is
much less than the decrease seen in cells extracted from the ICM
or following naive reprogramming (reduction of ~40% in CpG
methylation in ICM or naïve human ES cells48). Furthermore,
one clone appeared more responsive to low oxygen than the
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other, making it difficult to accurately assess the effect of this
condition on DNA methylation. We also saw significant hyper-
methylation of CpG island-containing promoters following
subcloning of MShef4. This hypermethylation had occurred in
multiple independent subclones, suggesting a global effect across
the entire cohort. This event might be a stress-induced response
to single-cell cloning and is worth considering in the context of
PSC maintenance, given the dynamic nature of epigenetic
change in PSCs. Finally, we saw a significant variation in the
expression of imprinted genes and the methylation status of
imprint control regions (ICRs). Overall, we detected variability
in ICR methylation in subclones, compared to their parental
clones or the starting cultures from which they were derived.
MShef4 subclones exhibited a different pattern of imprint
expression to MShef11 subclones, with little variation between
subclones. For some imprints, MShef11 subclones showed sig-
nificant subclonal variation, and we were able to detect specific
instances in which changes in ICR methylation correlated with
changes in accompanying imprint expression. These findings
suggest that DNA methylation is highly dynamic, responsive to
growth-conditions and culture practices, and can vary in a cell-
line-specific manner. However, as we did not find a correlation
between epigenetic change and mutation, the two may be
unrelated forms of variation.
Overall, the striking conclusion from this study is the low
mutation rate in human PSC, whether affecting SNV or INDELS,
despite the frequent reports of common genetic variants in the
literature. Most likely, the latter reflects an ascertainment bias. In
the ISCI study of 120 pairs of human PSC in early and late
passage, 79 lines remained karyotypically normal2 while in a
sequencing study of 140 human ES cell lines12, only six acquired
mutations in TP53, all results consistent with an underlying low
mutation rate in human PSC. Of course, one unknown is whether
PSC lines that have acquired growth advantages through long
periods in culture may have an altered mutation rate, perhaps a
mutator phenotype. Evidently, the mutation burden in human
PSC can be reduced by culture conditions, such in a low oxygen
environment, but it seems that the appearance of common var-
iants is largely a consequence of selection rather than underlying
mutation. Minimising the appearance of such variants will, then,
depend primarily upon identification and moderating of the
mechanisms by which they exhibit a growth advantage.
Methods
Cell lines and culture methods. Derivation and maintenance of the MShef4 and
MShef11 cell lines was performed in the Sheffield Centre for Stem Cell Biology
under HFEA licence R0115-8-A (Centre 0191) and HTA licence 22510, in a clean
room setting, following strict standard operating procedures. The embryos used to
derive MShef4 (frozen embryo) and MShef11 (fresh embryo) were donated from
different Assisted Conception Units, and so likely from different donors, following
fully informed consent, with no financial benefit to the donors, and were surplus or
unsuitable for their IVF treatment. Briefly, the embryos, were cultured using
standard IVF culture media (Medicult), to the blastocyst stage. Following removal
of the trophectoderm using a dissection laser the embryos were explanted whole
onto either mitotically inactivated human neonatal fibroblasts (human feeders) in
standard KOSR/KODMEM (Life Technologies) medium in the case of MShef4 or
onto Laminin-511 (Biolamina) and Nutristem medium (Biological Industries) in
the case of MShef11. Both cell lines were initially maintained at 37oC under 5% O2/
5% CO2, until the lines were established, after which maintenance switched 5%
CO2 in air at 37 °C. Cultures were passaged using a manual technique, cutting
selected colonies under a dissection microscope at an average split ratio of 1:2 every
7 days. Both lines have been deposited at the UK Stem Cell bank.
Parental material for these experiments was taken from fully characterised
research bank frozen stocks known to contain high quality undifferentiated human
ES cells, with a normal 46, XY karyotype frozen at passage P36 (MShef4) and P15
(MShef11). Cells were thawed onto mitomycin C-inactivated human fibroblast
feeders, maintained in Nutristem and passaged using the manual cutting technique.
After expansion for seven (MShef4) and five (MShef11) passages, the lines were
cloned by single-cell deposition using a FACSJazz flow cytometer (Becton
Dickinson) into 96-well plates with human feeders, Nutristem medium and
Rho-Kinase (ROCK) inhibitor, Y2763249. After 24 h the medium was changed to
remove ROCK inhibitor and the developing clones observed over 2 weeks before
being manually picked and expanded in Nutristem on human feeders at 37 °C
under an atmosphere of 5% CO2 in air, without the use of Y27632. From each line
we selected a clone that we then recloned by single-cell deposition as above to yield
parent clones at passage levels P53 (MShef4) and P35 (MShef11) (Fig. 1) with
which to initiate the mutation analysis.
In the case of MShef4, we initially isolated ten parent clones by single-cell
deposition. At the earliest possible time during their expansion we carried out an
initial cytogenetic and SNP array screen to exclude any clones that may have
acquired gross karyotypic changes (Supplementary Table 4). A single parent clone
(designated B8) was selected for mutation analysis. This was grown under standard
growth-conditions (Nutristem medium and mitomycin C treated human fibroblast
feeders without the use of Y27632) for a total of 109 days (19 passages) following
single-cell deposition, after which a cohort of 20 subclones (Cohort J) was isolated
and expanded through a further five passages to provide sufficient DNA and RNA
for sequencing.
In the case of MShef11, a number of parent clones were similarly isolated but
then grown under one of three conditions: Ten clones were cultured under the
same standard conditions as the MShef4 clones, 10 clones were cultured under
similar conditions but with the ROCK inhibitor, Y27632, added during each
passage and 10 clones, to be maintained in low oxygen, were immediately
transferred after single-cell deposition to a Ruskinn Sci-tive Workstation (Ruskinn
Technology, Bridgend, Wales), equipped with an integrated microscope and
incubator so that the cells could be passaged continually under an atmosphere of
5% O2/5% CO2 in nitrogen without exposure to atmospheric oxygen. These clones
were expanded and screened as early as possible by cytogenetics and SNP array to
exclude gross variants, and genetically normal clones were carried forward for
further analysis (Supplementary Table 4). Two such parent clones (E4 and E7)
were grown under standard conditions, and two (F1 and F4) were grown in the
presence of the Rho-Kinase inhibitor at each passage, for 111 days (25 passages)
and 115 days (25 passages), respectively. We then produced two cohorts of
subclones from each parent clone for sequence analysis: Standard condition,
Cohorts O and P (10 and 9 subclones, respectively); Rho-Kinase inhibitor
condition, Cohorts K and L (10 subclones each). In the case of low oxygen, two
parent clones (G8 and G2) were grown for 111 days (25 passages) but for technical
reasons we were only able to produce nine viable subclones (Cohort N) from one of
these (clone G8). Therefore, a further cohort of 12 subclones (Cohort Q) was
derived from a continuation culture of the first low oxygen clone, G8, but only after
it had been removed from low oxygen at 111 days and maintained under standard
conditions for a further 28 days (six passages) (Fig. 1).
DNA sequencing. Genomic DNA was isolated (DNeasy kit, Qiagen) from each
parental cell line, all clones and subclones and used for whole-genome sequencing3
using the Illumina HiSeqX10 platform (Supplementary Data 15). For whole-
genome bisulphite (WGBS), libraries50 were prepared by sonicating 500 ng geno-
mic DNA using a Covaris Sonicator into 300-400 bp long fragments, followed by
end-repair, A-tailing and methylated adapter (Illumina) ligation using NEB-Next
reagents. Subsequently, libraries were bisulphite-treated using EZ DNA
Methylation-Direct Kit (Zymo), followed by library amplification with indexed
primers using KAPA HiFi Uracil+ HotStart DNA Polymerase (Roche). All
amplified libraries were purified using AMPure XP beads (Agencourt) and assessed
for quality and quantity using High-Sensitivity DNA chips on the Agilent Bioa-
nalyzer. High-throughput sequencing of all libraries was carried out with a 125 bp
paired-end protocol on a HiSeq 2000 instrument (Illumina). Raw sequence reads
from WGBS libraries were trimmed to remove poor quality reads and adapter
contamination, using Trim Galore (v0.4.4). The remaining sequences were mapped
using Bismark (v0.18.0)51 with default parameters to the human reference genome
GRCh38 in paired-end mode. Reads were deduplicated and CpG methylation calls
were extracted from the deduplicated mapping output using the Bismark methy-
lation extractor (v0.18.0) in paired-end mode. Clones grown in different conditions
were sequenced to 15–23X genomic coverage. Subclones were initially multiplexed
by group, resulting in 0.8X average coverage per subclone, and 16X average cov-
erage per group. Selected subclones were individually re-sequenced, resulting in
10X average coverage per subclone (Supplementary Data 16).
RNA sequencing. Total RNA was isolated using an RNeasy kit (Qiagen). Poly-A-
enriched libraries were generated at the Wellcome Trust Sanger Institute. RNA-seq
libraries were sequenced on Illumina HiSeq2500 by 75-bp paired-end sequencing.
Raw sequence reads were trimmed to remove poor quality reads and adaptor
contamination using Trim Galore and mapped to the human GRCh37 hs37d5
reference assembly accompanied by the Ensembl 75 human transcriptome anno-
tations with HiSAT2 (https://www.nature.com/articles/nmeth.3317). On average,
24X exonic coverage was obtained per subclone group (Supplementary Data 16).
Data processing and quality control. For WGS data, 150 bp paired-end trimmed
sequencing reads were aligned to the GRCh37 reference genome using BWA.
Marking of duplicates and their removal were performed using biobambam (www.
github.com/gt1/biobambam2). Mutations were then called using the CaVEMan
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(Cancer Variants Through Expectation Maximization) computational frame-
work25. All somatic mutations that passed the standard threshold established by
Alexandrov et al.25 were filtered for Median Alignment Score (ASMD) of reads
greater than 130, and no clipped bases were considered. This identified SNVs
present in each set of subclones from both lines and all culture conditions, by
subtracting the genetic variation in the relevant parental line for each subclone.
Annotated SNPs from the general population and matching with dbSNP entries,
which were present in the parental cultures and clones were also removed. From all
80 subclones from both cell lines and all culture conditions 19,579 de novo SNVs
(with respect to genomic position and base substitution) passed the initial quality
score criteria described above (Supplementary Figures 1-4; Supplementary Data 1).
Of these, we excluded 4069, which fell below an allelic frequency of 0.2. Addi-
tionally, we omitted from subsequent analyses one MShef11 subclone from the
+Y27632 culture condition, and one MShef11 subclone from the low oxygen
culture condition since both exhibited very high mutation rates with unusual mixed
allelic frequencies, most likely because they were not derived from single cells. We
also excluded from the analysis a set of 2350 SNVs that recurred in two or more
subclones since they most likely represented mis-calls. After these eliminations, a
set of 12,555 SNVs remained and was used to calculate the mutation rates for each
cell line under each growth condition. In the case of INDELs we used the PINDEL
INDEL-calling algorithm (www.github.com/genome/pindel) to detect mutation; we
only considered those that passed a standard filtering score >250. From all
80 subclones from both cell lines and all culture conditions 1884 INDELs passed
the initial quality score criteria described above (Supplementary Figs. 1-4; Sup-
plementary Data 3). Of these, we excluded 713 that fell below an allelic frequency
of 0.2 or the base length was greater than 100. We also excluded the two outlier
subclones as previously. After these eliminations, a set of 1171 INDELs remained
and was used to calculate the mutation rates for each cell line under each growth
condition.
RNA-seq data were analysed using the freely available sequence data analysis
software SeqMonk v1.38.2 (Andrews S; Babraham Bioinformatics, https://www.
bioinformatics.babraham.ac.uk/projects/seqmonk/). QC was performed using the
built-in SeqMonk RNA QC pipeline to assess data content and mapping efficiency.
Genome features were derived from the GRCh37 genome assembly in SeqMonk.
For inter-sample gene expression comparisons, data were quantified as non-
transcript-length-normalised counts (fragments per million reads) of merged
transcript isoforms, using the SeqMonk RNA-seq quantification pipeline. For
analysis of gene expression within a single sample, data were quantified as
transcript length-normalised counts (fragments per kilobase per million reads) of
merged transcript isoforms, using the SeqMonk RNA-seq quantification pipeline.
Bisulphite data was also analysed using SeqMonk v1.38.2 (Andrews S;
Babraham Bioinformatics, https://www.bioinformatics.babraham.ac.uk/projects/
seqmonk/). Quality control was performed within SeqMonk to assess average read
coverage and depth over features of interest. Duplicate parental clones cultured in
different growth-conditions were analysed as replicate sets; multiple subclones
derived from each condition were analysed as grouped data. Analysis was
performed using built-in bisulphite quantification pipelines, with the stringency of
analysis matched to the level and depth of coverage of samples.
Mutation signatures. All selected mutations were then used to extract mutational
signatures. For this purpose, the matrix decomposition algorithm was used as
implemented in the R package SomaticSignatures52. SomaticSignatures identifies
mutational signatures using the methodology described by Nik-Zainal24. Signatures
identified were then compared with the set of somatic mutations identified by
Alexandrov et al.25 using deconstructSig and mutationalPatterns packages in R.
Cosine similarity was used to rank the signature against the catalogue.
Rate calculations and statistical analysis. Genome mutation rates were calcu-
lated by dividing the number of mutations per replicate subclone by the number of
days maintained in culture, then by the total number of sequenced base-pairs in the
GRCh37 genome assembly21. Mutation rates of individual chromosomes or
selected genomic features were calculated by dividing the number of mutations per
subclone by the number of days in culture, then by the total base-pair content of
each chromosome or genomic feature. In all calculations, rates were normalised to
account for two copies of each autosome.
To test for differences between the mutation rates of growth-condition groups,
we first used D’Agostino & Pearson and Shapiro-Wilk normality tests to measure
the distribution of the data. Data that passed both tests at P= < 0.05 were
considered normally distributed. When data were normally distributed, we used
Student’s t-test with Welch’s correction to correct for unequal standard deviations.
When one or both sets of data were not normally distributed, we used non-
parametric Mann-Whitney rank testing.
To identify chromosomes with mutation rates that varied significantly from the
genome-wide rate, we first used D’Agostino & Pearson and Shapiro-Wilk
normality tests to measure the distribution of the data for each chromosome and
for the genome-wide rate. Data that passed both tests at P= < 0.05 were considered
normally distributed. In each growth-condition individual chromosomes were
compared with the respective genome-wide rate on a pairwise basis. When both the
chromosomal and genome-wide data were normally distributed, we compared
them using Student’s t-test with Welch’s correction to correct for unequal standard
deviations. When one or both of the chromosomal or genome-wide data were not
normally distributed we used non-parametric Mann-Whitney rank testing. Data
were corrected for multiple tests (22 tests x 4 growth conditions= 88 tests) using
the Bonferroni method to produce adjusted P-values.
Intronic and exonic regions were classified based on their annotated positions
in the GRCh37 genome assembly. Intergenic DNA was classified as regions
between annotated genic regions and was mutually exclusive to the exonic and
intronic regions. Unsequenced regions of intergenic DNA (including the ends of
some chromosomes, and at centromeric regions) were excluded from the analysis.
To calculate mutation rates the number of SNVs falling in each region was divided
by the total genomic DNA content of those regions, accounting for two copies of
each autosome. Other genomic regions were identified according to annotation
tracks from the Ensembl and ENCODE (https://www.encodeproject.org/reference-
epigenomes/ENCSR323FKB/) websites.
For mutations falling within annotated genes, the distance of each SNVs relative
to the TSS was calculated. TSS were identified based on annotations from the
UCSC table browser. Mutations in genes were then binned into 1000 bp bins
relative to their respective TSS, with increasing distance from the TSS. For each bin,
the proportion of genes with a mutation at that distance from the TSS was
calculated with relative to the total number of genes per bin, based on all those in
the GRCh37 genome assembly.
FPKM values for mutated genes were calculated using SeqMonk software and
combined with mutation rate data derived from CaVEMan. Log transformed
values were checked for normality of distribution in Prism 6, then correlated by
Spearman Product Moment testing using the base R function cor.test and the in-
built Prism 6 correlation test. The LMER was implemented using the function lmer
() in R within the package lme4.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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